Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Her-2 Negative Breast Cancer × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 34 Carcinoma, Non-Small-Cell Lung 24 Triple Negative Breast Neoplasms 21 Stomach Neoplasms 19 Nasopharyngeal Carcinoma 19 Esophageal Neoplasms 17 Esophageal Squamous Cell Carcinoma 16 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 14 Colorectal Neoplasms 11 Uterine Cervical Neoplasms 10 Pancreatic Neoplasms 8 Sarcoma 7 Recurrence 7 Neoplasm Metastasis 7 Lung Neoplasms 7 Melanoma 6 Liver Neoplasms 5 Hodgkin Disease 5 Cholangiocarcinoma 5 Biliary Tract Neoplasms 5 Small Cell Lung Carcinoma 4 Neoplasms 4 Advanced Gastric Cancer 4 Solid Tumor 3 Rectal Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Osteosarcoma 3 Nasopharyngeal Neoplasms 3 Locally Advanced Gastric Cancer 3

Interventions

fluzoparib 1 camrelizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05761470 2023-03-09

IMPARP

First Affiliated Hospital, Sun Yat-Sen University

Phase 2 Recruiting

Her-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡